AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.52
-0.04 (-1.24%)
As of 2:26PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.56
Open3.57
Bid3.52 x 2100
Ask3.53 x 2500
Day's Range3.51 - 3.63
52 Week Range3.20 - 5.45
Volume575,365
Avg. Volume1,438,150
Market Cap352.243M
Beta2.90
PE Ratio (TTM)N/A
EPS (TTM)-1.18
Earnings DateJul 28, 2017 - Jul 31, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • Capital Cube7 days ago

    ETFs with exposure to Agenus, Inc. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agenus, Inc. Here are 5 ETFs with the largest exposure to AGEN-US. Comparing the performance and risk of Agenus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Agenus Inc (AGEN)’s Earnings Grew 12.7%, Is It Enough?
    Simply Wall St.17 days ago

    Agenus Inc (AGEN)’s Earnings Grew 12.7%, Is It Enough?

    Understanding Agenus Inc’s (NASDAQ:AGEN) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...

  • Capital Cube18 days ago

    ETFs with exposure to Agenus, Inc. : November 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agenus, Inc. Here are 5 ETFs with the largest exposure to AGEN-US. Comparing the performance and risk of Agenus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Agenus, Inc. :AGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube19 days ago

    Agenus, Inc. :AGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Agenus, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Agenus, Inc. – Idera Pharmaceuticals, Inc., Cascadian Therapeutics Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Johnson & Johnson, ImmunoCellular Therapeutics, Ltd., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc. ... Read more (Read more...)

  • ACCESSWIRE24 days ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Agenus Inc.

    NEW YORK, NY / ACCESSWIRE / November 24, 2017 / Shares of Ampio blew up on Wednesday after encouraging data was published in a peer review journal about its Ampion serum that is being developed to treat ...

  • PR Newswirelast month

    Agenus Receives License Fee of $4 Million USD from Merck

    LEXINGTON, Mass., Nov. 15, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license and research collaboration agreement with Merck, known as MSD outside the United States and Canada. As previously announced, Merck is responsible for all future product development expenses for the selected antibody and Agenus is eligible to receive up to an additional $99 million in milestone payments, as well as royalties on worldwide product sales. "We are very pleased with the progress of our collaboration with Merck and the advancement of this antibody towards the clinic," said Garo Armen, Ph.D. Chairman and CEO of Agenus.

  • PR Newswirelast month

    Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA-4) and AGEN2034 (PD-1) at SITC 2017

    LEXINGTON, Mass., Nov. 9, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that data on AGEN1884 (CTLA-4) and AGEN2034 (PD-1) demonstrated that the molecules achieved the desired pharmacologic function and combination synergy will be presented at the Society for Immunotherapy of Cancer's (SITC) 31st Annual Meeting, Nov. 9-13th.  Agenus recently announced the launch of three clinical programs with these lead antibodies designed as potential pivotal programs to support BLA filings as soon as 2H 2019.  These milestones are additional evidence of Agenus delivering against its I-O strategy.

  • PR Newswirelast month

    Agenus to Present at the Jefferies Global Healthcare Conference in London

    LEXINGTON, Mass., Nov. 8, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, and Michael Plater, Ph.D., Chief Business Officer, Agenus, will make a presentation and host one-on one meetings with investors at the Jefferies Global Healthcare Conference at the Waldorf Hilton in London, U.K. on Wednesday, November 15, 2017.  The Company's presentation will take place at 8:00 a.m. GMT.

  • Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
    Zackslast month

    Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

    Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.

  • Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus
    Zackslast month

    Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

    Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of AGEN earnings conference call or presentation 7-Nov-17 4:00pm GMT

    Q3 2017 Agenus Inc Earnings Call

  • Agenus (AGEN) Reports In Line Q3 Loss, Sales Miss Estimates
    Zackslast month

    Agenus (AGEN) Reports In Line Q3 Loss, Sales Miss Estimates

    Agenus reported in line loss in the third quarter of 2017 but sales missed expectations.

  • Associated Presslast month

    Agenus reports 3Q loss

    The Lexington, Massachusetts-based company said it had a loss of 37 cents per share. The biotechnology company posted revenue of $3.4 million in the period. The company's shares closed at $3.67. A year ...

  • PR Newswirelast month

    Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update

    Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint ...

  • ACCESSWIRElast month

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 11:00 AM Eastern Time. To ...

  • GlobeNewswirelast month

    New Research: Key Drivers of Growth for Coty, Bristol-Myers Squibb, Carnival, Agenus, Steel Dynamics, and Impax Labs - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 07, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coty ...

  • Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised
    Zackslast month

    Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

    Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

  • Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View
    Zacks2 months ago

    Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

    Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.

  • Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View
    Zacks2 months ago

    Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View

    Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.

  • Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y
    Zacks2 months ago

    Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y

    Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.

  • Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View
    Zacks2 months ago

    Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View

    Alkermes' (ALKS) earnings beat estimates but sales lagged the same in the third quarter of 2017.

  • PR Newswire2 months ago

    Agenus to Report Third Quarter 2017 Financial Results on November 7, 2017 and Host Conference Call and Webcast

    LEXINGTON, Mass., Oct. 26, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2017 financial results before the market opens on Tuesday, November 7, 2017. Agenus executives will host a conference call and webcast at 11:00 a.m. ET the same day. The call will also be webcast and will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/23075.

  • Capital Cube2 months ago

    Agenus, Inc. – Value Analysis (NASDAQ:AGEN) : October 26, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Agenus, Inc. a score of 18. Our analysis is based on comparing Agenus, Inc. with the following peers – Idera Pharmaceuticals, Inc., Cascadian Therapeutics Inc., Northwest Biotherapeutics, Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Johnson & Johnson, ImmunoCellular Therapeutics, Ltd., Bristol-Myers Squibb Company, Celldex Therapeutics, ... Read more (Read more...)

  • PR Newswire2 months ago

    Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles

    LEXINGTON, Mass. , Oct. 25, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US ...

  • Capital Cube2 months ago

    ETFs with exposure to Agenus, Inc. : October 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agenus, Inc. Here are 5 ETFs with the largest exposure to AGEN-US. Comparing the performance and risk of Agenus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)